{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-008849","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.204597+00:00","generated_at":"2026-06-25T15:13:34.587078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal","bullets":["Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.","Revenue $1.4M vs $5.3M Q1 2021; $19M in milestone/initiation fees deferred for future recognition.","R&D expenses $16.6M (down from $20.2M); net loss $18.0M vs $17.2M in prior-year quarter.","Gilead HIV program advanced: $4M milestone, $15M initiation fee, $35M equity commitment; up to $237M milestones plus royalties.","HB-200 Phase 1 data due mid-2022; Phase 2 combo with pembrolizumab data in 2H 2022; prostate cancer IND expected Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-008849","json":"https://secwatch.observer/filing/0001558370-22-008849.json","markdown":"https://secwatch.observer/filing/0001558370-22-008849.md","text":"https://secwatch.observer/filing/0001558370-22-008849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/0001558370-22-008849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/hook-20220516x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:13:34.587078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}